Effects of Adjuvants on the Safety and Immanogenicity of an Avian Influenza H5N1 Vaccine in Adults

Bernstein, David I.; Edwards, Kathryn M.; Dekker, Cornelia L.; Belshe, Robert; Talbot, Helen K. B.; Graham, Irene L.; Noah, Diana L.; Fenhua He; Hill, Heather
March 2008
Journal of Infectious Diseases;3/1/2008, Vol. 197 Issue 5, p667
Academic Journal
Background. Influenza A H5N1 viruses pose a significant threat to human health. Methods. We conducted a multicenter, randomized, double-blind study in 394 healthy adults. Subjects were randomly assigned to receive 2 intramuscular doses of either saline placebo; influenza A/Vietnam! I 203/2004(H5N1) vaccine alone at 45, 30, or 15 µg per dose; vaccine at 15 or 7.5 µg per dose with MF59; or vaccine at 30, 15, or 7.5 µg per dose with aluminum hydroxide. Subjects were followed up for safety and blood samples were obtained to deter- mine antibody responses. Results. The vaccine formulations were well tolerated but local adverse effects were common; the incidence of these effects increased in a dose-dependent manner and was increased by the addition of adjuvants. The addition of MF59 increased the antibody response, whereas the addition of aluminum hydroxide did not. The highest antibody responses were seen in the group that received 15 µg of vaccine per dose with MF59, in which 63% of subjects achieved the predetermined endpoint (hemagglutination-inhibition titer ⩾40) 28 days after the second dose, compared with 29% in the group that received the highest dose (45 jµg per dose) of vaccine alone. Conclusions. A 2-dose regimen of subvirion influenza A (H5N1) vaccine was well tolerated. The antibody re- sponses to 15 µg of A/H5 vaccine with MF59 were higher than the responses to 45 µg of vaccine alone.


Related Articles

  • Avian Influenza and the Significance of Us Transmission to Humans--Information from WHO.  // Journal of Environmental Health;Oct2005, Vol. 68 Issue 3, p41 

    The article presents information on Avian influenza. Avian influenza is caused by Type A strains of the influenza virus. First identified in Italy more than 100 years ago, the disease occurs worldwide. All birds are thought to be susceptible, although some species are more resistant to infection...

  • Update: Influenza Activity—United States and Worldwide, 2003-04 Season, and Composition of the 2004-05 Influenza Vaccine.  // JAMA: Journal of the American Medical Association;9/22/2004, Vol. 292 Issue 12, p1420 

    Presents a report that summarizes information collected by the World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System collaborating laboratories, state and local health departments, health-care providers and others related to influenza activity in the...

  • BYPASSING THE FLU BUG. Perry, Patrick // Saturday Evening Post;Nov/Dec2006, Vol. 278 Issue 6, p84 

    The article presents a conversation with William Schaffner, M.D. regarding the 2006-2007 influenza season. Dr. Schaffner answers questions related to the best time to get vaccinated, how to tell the flu from a cold, and common vaccination myths. Dr. Schaffner also answers questions about the...

  • When to Use Bird Flu Vaccine a "Tricky Issue".  // Clinical Infectious Diseases;2/1/2007, Vol. 44 Issue 3, piii 

    The article reports on the problem concerning the development of vaccine for the treatment of bird flu H5N1 avian influenza. The World Health Organization (WHO) stressed that the development of the vaccine may take 4-6 months before it will be released in the market. The organization stated the...

  • China's efforts at avian influenza treatment and prevention. Jinpei Li; Ruifang Fan; Yonggang Li; Xun Li // BioScience Trends;Feb2009, Vol. 3 Issue 1, p1 

    The article reports on the move of the Chinese government for the treatment and prevention of the unprecedented epizootic avian influenza virus known as A (H5N1) . It notes that the Chinese government has conducted an extensive dissemination of knowledge related to H5N1 to raise the awareness...

  • The changing ecology of avian flu. Weir, Erica // CMAJ: Canadian Medical Association Journal;10/11/2005, Vol. 173 Issue 8, p869 

    Offers information about avian influenza. Background and epidemiology; Source of interim guidelines on the clinical management of humans infected by avian influenza; Measures to contains an avian influenza pandemic.

  • Dead hen walking. Toohey, Paul // Bulletin with Newsweek;10/4/2005, Vol. 123 Issue 6490, p10 

    Offers views on avian flu in Indonesia. View that all flu has the potential to kill; Mention of residual immunity in humans to make the symptoms merely unpleasant, rather than fatal; Finding that Avian flu won't be truly dangerous until it can move from human to human.

  • Influenza A H5N1 Immigration Is Filtered Out at Some International Borders. Wallace, Robert G.; Fitch, Walter M. // PLoS ONE;2008, Vol. 3 Issue 2, p1 

    Background: Geographic spread of highly pathogenic influenza A H5N1, the bird flu strain, appears a necessary condition for accelerating the evolution of a related human-to-human infection. As H5N1 spreads the virus diversifies in response to the variety of socioecological environments...

  • Update: Influenza Activity -- United States, February 26-March 4, 2006.  // MMWR: Morbidity & Mortality Weekly Report;3/17/2006, Vol. 55 Issue 10, p284 

    Presents an update on influenza activity in the U.S. during February 26-March 4, 2006. Increase in the percentage of specimens testing positive for influenza; Percentage of outpatients visits for influenza-like illness and percentage of deaths attributed to pneumonia and influenza during the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics